{"id":399834,"date":"2020-12-15T08:07:06","date_gmt":"2020-12-15T13:07:06","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399834"},"modified":"2020-12-15T08:07:06","modified_gmt":"2020-12-15T13:07:06","slug":"diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/","title":{"rendered":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study<\/b><\/p>\n<p>MINNEAPOLIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company\u2019s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts.\n<\/p>\n<p>\nDiaMedica\u2019s Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and efficacy of multiple doses of DM199, administered over 90 days, in participants with CKD (Stage 2 or 3)<b \/>enrolling<b \/>approximately 90 participants in three cohorts (30 per cohort). Cohort 1 of the study is focused on non-diabetic, African Americans with hypertension, a group that is at greater risk for CKD than Caucasians. Additionally, the study is designed to identify African American participants with the APOL1 gene mutation as an exploratory biomarker as these individuals have an even higher risk of developing CKD. Cohort 2 of the study is focused on participants with IgA Nephropathy (IgAN) and Cohort 3 includes participants with diabetic kidney disease.\n<\/p>\n<p>\n\u201cWe\u2019re very grateful to the participants and research site staff for their dedication and commitment in moving the REDUX study forward during this challenging time of Covid-19,\u201d stated DiaMedica\u2019s Chief Medical Officer Dr. Harry Alcorn, Jr. \u201cGiven the positive results observed earlier this year in the subset of diabetic participants in our Phase 2 stroke study, we are looking forward to announcing topline results, anticipated in the second quarter of 2021.\u201d\n<\/p>\n<p><b><i>About DiaMedica Therapeutics Inc.<\/i><\/b><\/p>\n<p>\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and chronic kidney diseases. DiaMedica shares are listed on The Nasdaq Capital Market under the trading symbol \u201cDMAC.\u201d\n<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=52348329&amp;newsitemid=20201215005118&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=1&amp;md5=04014d297be6e1a34a9a95517d7f68f4\">www.diamedica.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201215005118\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201215005118\/en\/<\/a><\/span><\/p>\n<p>\nScott Kellen<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>Phone: (763) 496-5118<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:skellen@diamedica.com\">skellen@diamedica.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Minnesota United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201215005118\/en\/749392\/3\/DiaMedica-Logo-white-background.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company\u2019s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts. DiaMedica\u2019s Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and efficacy of multiple doses of DM199, administered over 90 days, in participants with CKD (Stage 2 or 3)enrollingapproximately 90 participants in three cohorts (30 per cohort). Cohort 1 of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399834","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company\u2019s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts. DiaMedica\u2019s Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and efficacy of multiple doses of DM199, administered over 90 days, in participants with CKD (Stage 2 or 3)enrollingapproximately 90 participants in three cohorts (30 per cohort). Cohort 1 of the &hellip; Continue reading &quot;DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T13:07:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study\",\"datePublished\":\"2020-12-15T13:07:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/\",\"name\":\"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-15T13:07:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/","og_locale":"en_US","og_type":"article","og_title":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk","og_description":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company\u2019s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts. DiaMedica\u2019s Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and efficacy of multiple doses of DM199, administered over 90 days, in participants with CKD (Stage 2 or 3)enrollingapproximately 90 participants in three cohorts (30 per cohort). Cohort 1 of the &hellip; Continue reading \"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T13:07:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study","datePublished":"2020-12-15T13:07:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/","name":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-15T13:07:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201215005118r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-announces-enrollment-of-last-patient-in-diabetic-kidney-disease-cohort-of-phase-2-redux-ckd-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399834"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399834\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}